Screening: In-Depth Focus 2014
Posted: 5 January 2015 | European Pharmaceutical Review
This free-to-view Screening In-Depth Focus is packed with articles that will give you a greater understanding of interesting topics such as the identification of compounds that protect against free radicals, advancements in sandwich immunoassay techniques and hit validation and optimisation…
- Assay techniques for the identification of compounds that protect against free radicals
Peter McDonald and Anuradha Roy, University of Kansas
The biology and the chemistry of free radical generation and their effects on cell physiology in homeostasis and disease have been reviewed extensively. Aerobic reactions in mitochondria, endoplasmic reticulum and peroxisomes result in accumulation of oxygen-derived reactive molecules and free radicals as byproducts. ROS (Reactive Oxygen Species) are also generated by radiation and from the metabolism of various drugs, oxidation of phenols or aromatic amines and compound autoxidation catalysed by transition metal ions. Being short-lived and unstable, the reactive oxygen species manifest their effects by readily reacting with other cellular chemical species..
- Hit validation and optimisation in earlystage drug discovery
Michelle Arkin and Jeff Neitz, Small Molecule Discovery Center, UCSF
In drug discovery, the process of developing an initial ‘hit’ compound into a bona fide lead is idiosyncratic. This article describes the general process for this ‘hit-to-lead’ phase, starting from validation of hits arising from screening. The decision workflow for compound optimisation will depend on the target profile for the eventual drug. It is important to select hits based on biological mechanism and physicochemical properties…
- The role and future of sandwich immunoassays in phenotypic screening
Steve Ludbrook, Rob Jepras and Gareth Wayne, GlaxoSmithKline
Sandwich immunoassays are in widespread use across research and clinical applications as gold-standard methods for the accurate detection of protein analytes. With the renaissance in phenotypic assay approaches for pre-clinical drug discovery, recent advances in higher throughput aligned sandwich immunoassay technologies are enabling this method to be utilised earlier in the drug discovery process, enabling clinically relevant assays to be interrogated up to high throughput screening scales. Rapid progress in miniaturisation approaches should maintain and increase the use of such assays at the front end of drug discovery approaches…
This Screening In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!